Erenumab + calcitonin gene-related peptide for migraine disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Oct 2020: Trial started, NCT04592952
  2. 19 Oct 2020: Trial registered, NCT04592952

The trials

NCT04592952: Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab

State
State not given
Phase
Phase 4
People
400 planned
Started
8 Oct 2020
Primary completion
1 Aug 2025
Arms
Single-Arm
Results
None posted
  1. 8 Oct 2020: Trial started
  2. 19 Oct 2020: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.